HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Genmab (NASDAQ:GMAB) and maintained a $50 price target, indicating confidence in the company's future performance.
September 16, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Genmab, maintaining a $50 price target. This suggests continued confidence in Genmab's potential growth and performance.
The reiteration of a Buy rating and maintenance of a $50 price target by HC Wainwright & Co. indicates strong confidence in Genmab's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in GMAB's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100